Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 07, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 3,500,000 ordinary shares.
- Purchase Price: 1,047.55 pence per share.
- Transaction Date: March 06, 2008.
Material Changes
Following the cancellation of the repurchased shares, the company's capital structure has been updated as follows:
- Treasury Shares: The company now holds 504,194,158 shares in Treasury, representing 9.24% of total voting rights.
- Shares in Issue: There are 5,456,822,484 shares in issue (excluding Treasury shares), which represents the total voting rights in the company.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the updated total number of shares in issue (5,456,822,484) for calculating ownership percentages under Disclosure and Transparency Rules.
- Confirm the Treasury share count (504,194,158) and its impact on the 9.24% voting rights representation.
- Note that this filing is a notification of a completed share cancellation and does not contain operational or financial performance data for the period.